Table 1 Baseline characteristics for total cohort
From: A new paradigm evaluating cost per cure of HCV infection in the UK
All patients (n = 154) | |
|---|---|
Age [Mean, (SD)] | 49.6 (9.01) |
Gender | |
Male [%] | 73.4 % |
Female [%] | 26.6 % |
Ethnicity | |
White [%] | 94.2 % |
Liver disease (Metavir stage) | |
Non-cirrhotic (F0-F3) [%] | 78.6 % |
Cirrhotic (F4 including 1 HCC) [%] | 21.4 % |
Treatment history | |
Experienced [%] | 52.0 % |
Naïve [%] | 48.0 % |
Response to previous therapy | |
Relapse [%] | 43.7 % |
No response [%] | 45.0 % |
Missing [%] | 11.3 % |
HCV genotype | |
Genotype 1a [%] | 51.3 % |
Genotype 1b [%] | 18.8 % |
G1 subtype Missing [%] | 29.9 % |
HCV therapy | |
Telaprevir treatment [%] | 69.1 % |
Boceprevir treatment [%] | 33.1 % |
IL28B status (SNP rs12979860) | |
Heterozygous CT [%] | 56.9 % |
Homozygous CC [%] | 29.4 % |
Homozygous TT [%] | 13.7 % |
Missing [%] | 0.7 % |
Comorbidities | |
Depression [%] | 26.0 % |
HIV co-infection [%] | 6.5 % |
Diabetes [%] | 5.2 % |
Haemophilia [%] | 5.2 % |
Cancer [%] | 3.9 % |
Renal failure [%] | 0.7 % |